ASF 1020

Drug Profile

ASF 1020

Alternative Names: ASF-1020

Latest Information Update: 26 Jan 2011

Price : $50

At a glance

  • Originator Astion Pharma A/S
  • Class Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 24 Mar 2006 Phase-I/II clinical trials in Asthma in Denmark (Inhalation)
  • 24 Mar 2006 ASF 1020 is available for licensing worldwide (http://www.astion.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top